# Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia

> **NCT04902781** · PHASE2,PHASE3 · COMPLETED · sponsor: **Applied Therapeutics, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Classic Galactosemia

## Interventions

- **DRUG:** AT-007
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04902781
- **Lead sponsor:** Applied Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-20
- **Primary completion:** 2023-03-03
- **Final completion:** 2025-05-21
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04902781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04902781, "Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04902781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*